The drastic reduction in the price target from $23 to $3 suggests a significant change in the analyst's outlook on Marinus Pharma's future performance. While the Buy rating is maintained, the new price target indicates a much lower expected valuation, which could lead to a negative short-term impact on the stock price as investors reassess their positions.